(Q50082633)

English

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.

scientific article published on 23 October 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

0 references

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. (English)

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

Stephan Windecker

7

object named as

Stephan Windecker

1 reference

Europe PubMed Central

24 February 2018

5

object named as

Lorenz Räber

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

George C M Siontis

2

object named as

George C M Siontis

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

6

object named as

François Mach

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

author name string

Konstantinos C Koskinas

1

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

Raffaele Piccolo

3

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

Dimitris Mavridis

4

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

publication date

23 October 2017

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

European Heart Journal

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Exploring and accounting for publication bias in mental health: a brief overview of methods.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

How should meta-regression analyses be undertaken and interpreted?

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHX566

21 January 2018

Identifiers

10.1093/EURHEARTJ/EHX566

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/29069377

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50082633&oldid=1739186015"